about
sameAs
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryHigh levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetesHuman thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysisCorrelation between albuminuria and spontaneous platelet microaggregate formation in type 2 diabetic patientsEffects of blood pressure and the renin-angiotensin system on platelet activation in type 2 diabetes.Acetylsalicylic Acid resistance in patients with type 2 diabetes mellitus, prediabetes & non-diabetic coronary artery disease.Effects of Ramadan fasting on platelet reactivity in diabetic patients treated with clopidogrel.Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent.A novel small molecule 1,2,3,4,6-penta-O-galloyl-α-D-glucopyranose mimics the antiplatelet actions of insulinImpact of age, CYP2C9 genotype and concomitant medication on the rate of rise for prothrombin time during the first 30 days of warfarin therapy.Inhibitory effects of kiwifruit extract on human platelet aggregation and plasma angiotensin-converting enzyme activity.Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation.Clinical importance of aspirin and clopidogrel resistanceMean platelet volume and platelet counts in type 2 diabetes: mellitus on treatment and non-diabetic mellitus controls in Lagos, Nigeria.Coupling factor 6 enhances the spontaneous microaggregation of platelets by decreasing cytosolic cAMP irrespective of antiplatelet therapy.Effect of common single nucleotide polymorphisms in COX-1 gene on related metabolic activity in diabetic patients treated with acetylsalicylic acidDetection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.Interleukin-1 and acute brain injury.Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes.Low dose of acetylsalicylic acid and oxidative stress-mediated endothelial dysfunction in diabetes: a short-term evaluation.Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane.High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study.Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapyType 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant StressPlatelet isoprostane overproduction in diabetic patients treated with aspirin.Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus: What the Data Show Us.Unaltered Angiogenesis-Regulating Activities of Platelets in Mild Type 2 Diabetes Mellitus despite a Marked Platelet HyperreactivityGlycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum.N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial.Reduction of CTRP9, a novel anti-platelet adipokine, contributes to abnormal platelet activity in diabetic animals.Diabetes and stroke prevention: a review.Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents.Glycoxidized HDL, HDL enriched with oxidized phospholipids and HDL from diabetic patients inhibit platelet function.Relationship between Altered Platelet Morphological Parameters and Retinopathy in Patients with Type 2 Diabetes Mellitus.Losartan and ozagrel reverse retinal arteriolar constriction in non-obese diabetic miceOzagrel reverses streptozotocin-induced constriction of arterioles in rat retinaRandomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetesPhysiology and pathophysiology of canonical transient receptor potential channelsDiabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularizationPlatelet hyperactivity in type 2 diabetes: role of antiplatelet agents.
P2860
Q22241786-43E5FBD0-D56B-4233-9F47-EFF29D31D43CQ28222494-2388C7CF-7A3A-4B72-A5EC-9DB67409EED8Q28534432-5778BE54-EA23-4E25-8C1E-463799A5ECCBQ33493041-5C12A735-8ADB-4D7B-9B21-7890B6E8B19FQ33609751-9171AEBF-BEFF-422F-B5B3-6A1D80D9CCCDQ33722562-A2B3476C-7AE3-4F21-93A7-7AA838E8CD02Q33760007-BCB0873A-B537-4BB5-8B56-56E3C4C01F67Q33873092-98B78291-E0D1-4EB8-B71E-0ACA777ABB5DQ34071537-FCF4C007-161B-42A9-BABD-81D37A075341Q34146486-9BE30734-BB02-43B8-B5FB-C094B04A5F0DQ34384376-57BA4129-E24D-4E31-A606-EC3170690AAFQ34389439-8E561570-6562-4BFB-AB80-123A0E21B19CQ34390050-C9E21390-F204-46E6-ACB7-4516F40DF5C9Q34431756-9C12ABEC-18BD-4839-A572-6821F89AB15BQ34579200-6ACEF4BD-69B5-45BA-838B-81F1C407F864Q34974280-06164A6F-4E10-4A96-9143-EDD0C38915A4Q35033557-B0C98E7C-DE9C-4484-9FFB-1A9988732C4AQ35056860-BE26E232-7A5E-471A-9B5A-F850A5170E1BQ35061063-96C5B661-307B-4160-A10F-1457453E924CQ35218036-115F5E01-D2F6-40A5-BEE6-0E1E56871AC3Q35485016-17B837E2-47FF-45C1-99F6-A813F957B52FQ35736714-936A4D2B-5C42-4558-A6F6-F5E87D8DA600Q35755253-452CDC36-91D9-4350-B2F3-F2E1BC897C6BQ35782187-12637A37-52B5-4199-B306-ECA71A2C58F9Q35976574-E2A386FA-704F-43BB-9FEE-C4F94F3085B4Q36094523-BE6139E0-BEB8-408D-97D2-6572AD55AFCFQ36128546-A9AC9021-A34F-403A-AB8C-96ECAF72C564Q36194911-3393910A-95CA-4A33-B2D0-E97790C4F780Q36297823-60CC5E23-2C19-4C5B-89FB-E828A60272B1Q36454417-DB3E6482-FC5C-4D84-9489-4E6DDA2EBD6CQ36528473-B7801211-3BFB-41C5-AC06-C0DED71BB056Q36649824-DADD6B4A-B3B6-4904-9F17-EB69DC16310AQ36718110-B44FB3CE-2266-44B3-9F29-1675B5A25B74Q36835245-56A119ED-08D3-40F6-A323-EF4D43DEC08FQ36857431-1E6B0626-1E86-44C1-8F8B-B3510A4BFC9BQ37012608-B00ECEC8-D7D7-4E41-9163-2BB1678B5CCCQ37022618-8D4B862F-F43D-4670-BFBB-4F1E1907A3E1Q37072447-F5ECEDAF-2749-45F5-8380-9E4A62B5A037Q37167506-9995DBC4-2CD9-42D7-AB8D-5A7753D71ACEQ37184596-24D1B933-6E37-499F-BD96-180DA6CA7E36
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Platelet activation in type 2 diabetes mellitus
@ast
Platelet activation in type 2 diabetes mellitus
@en
Platelet activation in type 2 diabetes mellitus
@nl
type
label
Platelet activation in type 2 diabetes mellitus
@ast
Platelet activation in type 2 diabetes mellitus
@en
Platelet activation in type 2 diabetes mellitus
@nl
prefLabel
Platelet activation in type 2 diabetes mellitus
@ast
Platelet activation in type 2 diabetes mellitus
@en
Platelet activation in type 2 diabetes mellitus
@nl
P2860
P3181
P1476
Platelet activation in type 2 diabetes mellitus
@en
P2860
P304
P3181
P356
10.1111/J.1538-7836.2004.00836.X
P407
P577
2004-08-01T00:00:00Z